FDA expands Repatha indication to adults at risk of major cardiovascular events from uncontrolled LDL-C
The FDA also expanded Repatha’s use as monotherapy to include patients with homozygous familial hypercholesterolemia
The FDA also expanded Repatha’s use as monotherapy to include patients with homozygous familial hypercholesterolemia
Earlier in July 2025, Dazublys has received the marketing authorisation in the European Union from the European Commission
The product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), VASOSTRICT Injection 40 Units per 100 mL and 20 Units per 100 mL of PH Health Limited
The complex four-hour surgery was performed by a multidisciplinary team of doctors
Dawnzera demonstrated significant and sustained HAE attack rate reduction and long-term disease control
NATCO holds the first-to-file status for this product and will have 180-day generic drug exclusivity
This acquisition expands HGM's healthcare platform capabilities in revenue cycle management
Projects 5X revenue growth by 2028, accelerates global market leadership and paves the way for IPO
Macitentan tablets are an endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension
Subscribe To Our Newsletter & Stay Updated